Nagao T, Koseki J, Suzuki Y, Nagamatsu T
Department of Pharmacology, Faculty of Pharmacy, Meijo University, 150 Yagotoyama Tenpaku-Ku, Nagoya 468-8503, Japan.
Eur J Pharmacol. 2001 Feb 16;413(2-3):271-9. doi: 10.1016/s0014-2999(00)00932-8.
Recently, it has been demonstrated that the production of prostaglandins and thromboxane is increased in patients with chronic glomerulonephritis and lupus nephritis. We recently demonstrated that thromboxane A(2) delayed the clearance of heat-aggregated bovine serum albumin deposited in glomeruli. In the present study, we investigated the effect of thromboxane A(2) on the clearance of macromolecules in nephritic glomeruli. First, we attempted to clarify the conditions for the clearance of heat-aggregated bovine serum albumin in nephritic glomeruli, using glomeruli isolated from control and anti-glomerular basement membrane nephritic mice. Heat-aggregated bovine serum albumin was injected twice into each mouse. The glomeruli were then isolated and incubated in culture medium. The heat-aggregated bovine serum albumin content of control glomeruli gradually diminished with incubation time up to 24 h. The heat-aggregated bovine serum albumin content of nephritic glomeruli was 69% higher than that of control glomeruli at 24 h incubation. The production of thromboxane B(2) (the stable metabolite of thromboxane A(2)) in nephritic glomeruli showed about a sevenfold increase compared with control. DP-1904 [6-(1-imidazolylmethyl)-5,6,7,8-tetrahydro-naphthalene-2-carboxylic acid hydrochloride], a thromboxane A(2) synthase inhibitor, and KT2-962 [sodium 3-(4-(4-chlorophenyl-butylsulfonamido) butyl)-6-isopropylazulene-1-sulfonate], a selective thromboxane A(2) receptor antagonist, significantly reduced the heat-aggregated bovine serum albumin content in nephritic glomeruli. Normal glomeruli treated with U-46619 [15S-hydroxy-11a,9a-(epoxymethano)prosta-5Z,13E-dienoic acid], a stable analogue of thromboxane A(2), had significantly more heat-aggregated bovine serum albumin than control glomeruli. We next investigated whether thromboxane A(2) could affect the uptake/disposal of heat-aggregated bovine serum albumin by cultured rat mesangial cells. U-46619 significantly enhanced the uptake and inhibited the disposal of heat-aggregated bovine serum albumin by mesangial cells. Finally, we performed experiments to elucidate the role of the thromboxane A(2) receptor (TP receptor) in the clearance of heat-aggregated bovine serum albumin using TP-deficient mice. The glomerular heat-aggregated bovine serum albumin content of TP-receptor knockout [TP(-/-)] mice was lower than that of wild-type [WT(+/+)] mice. U-46619 dose dependently increased the uptake of heat-aggregated bovine serum albumin by mesangial cells in WT(+/+) mice, but not in the TP(-/-) mice. These findings suggest that thromboxane A(2) retards the clearance of aggregated protein in nephritic glomeruli and may contribute to the pathophysiology of glomerulonephritis.
最近,已证实慢性肾小球肾炎和狼疮性肾炎患者体内前列腺素和血栓素的生成增加。我们最近证明,血栓素A2会延迟肾小球中热聚集牛血清白蛋白的清除。在本研究中,我们调查了血栓素A2对肾炎性肾小球中大分子清除的影响。首先,我们试图利用从对照小鼠和抗肾小球基底膜肾炎小鼠分离出的肾小球,阐明肾炎性肾小球中热聚集牛血清白蛋白的清除条件。将热聚集牛血清白蛋白给每只小鼠注射两次。然后分离肾小球并在培养基中孵育。对照肾小球中热聚集牛血清白蛋白的含量随孵育时间逐渐减少,直至24小时。孵育24小时时,肾炎性肾小球中热聚集牛血清白蛋白的含量比对照肾小球高69%。与对照相比,肾炎性肾小球中血栓素B2(血栓素A2的稳定代谢产物)的生成增加了约7倍。血栓素A2合酶抑制剂DP - 1904 [6 - (1 - 咪唑基甲基)-5,6,7,8 - 四氢萘 - 2 - 羧酸盐酸盐]和选择性血栓素A2受体拮抗剂KT2 - 962 [3 - (4 - (4 - 氯苯基丁基磺酰胺基)丁基)-6 - 异丙基薁 - 1 - 磺酸钠]显著降低了肾炎性肾小球中热聚集牛血清白蛋白的含量。用血栓素A2的稳定类似物U - 46619 [15S - 羟基 - 11a,9a - (环氧亚甲基)前列腺 - 5Z,13E - 二烯酸]处理的正常肾小球,其热聚集牛血清白蛋白含量比对照肾小球显著更多。接下来,我们研究了血栓素A2是否会影响培养的大鼠系膜细胞对热聚集牛血清白蛋白的摄取/处理。U - 46619显著增强了系膜细胞对热聚集牛血清白蛋白的摄取并抑制了其处理。最后,我们使用TP缺陷小鼠进行实验,以阐明血栓素A2受体(TP受体)在热聚集牛血清白蛋白清除中的作用。TP受体敲除[TP(-/-)]小鼠的肾小球热聚集牛血清白蛋白含量低于野生型[WT(+/+)]小鼠。U - 46619剂量依赖性地增加了WT(+/+)小鼠系膜细胞对热聚集牛血清白蛋白的摄取,但在TP(-/-)小鼠中未增加。这些发现表明,血栓素A2会延缓肾炎性肾小球中聚集蛋白的清除,并可能参与肾小球肾炎的病理生理过程。